Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| VALN | EFFECT | neutral | 3/10 | Valneva SE's SEC registration statement (F-3, File No. 333-296504) became effective as of June 16, 2026, allowing the co | Jun 17, 2026 |
| IRD | EFFECT | bearish | 6/10 | Opus Genetics' S-3 resale shelf (filed June 5, 2026) has become effective, allowing selling stockholders Oberland Capita | Jun 17, 2026 |
| AIM | EFFECT | bearish | 7/10 | AIM ImmunoTech's S-1 registration statement (File No. 333-296588) became effective on June 16, 2026, allowing selling st | Jun 17, 2026 |
| MRNA | COURT-RULING | neutral | 2/10 | A Special Master in the District of Delaware denied GSK's motion to limit third-party inventor depositions to 10 combine | Jun 17, 2026 |
| PFE | COURT-RULING | neutral | 2/10 | A Special Master in the District of Delaware denied GSK's motion to limit Pfizer/BioNTech and Moderna to a combined 10 h | Jun 17, 2026 |
| GSK | COURT-RULING | bearish | 4/10 | GSK was denied a motion to limit third-party deposition hours in its patent infringement cases against Pfizer/BioNTech a | Jun 17, 2026 |
| KALV | EFFECT | neutral | 3/10 | KalVista Pharmaceuticals' shelf registration statement (Form S-3, File No. 333-280759) was declared effective by the SEC | Jun 17, 2026 |
| VYNE | EFFECT | neutral | 4/10 | VYNE Therapeutics' registration statement (S-4, file 333-294804) covering the merger or business combination was declare | Jun 17, 2026 |
| ARTV | INSIDER-BUY | bullish | 7/10 | RA Capital Management, a director and 10% owner, purchased 1.43 million shares of Artiva Biotherapeutics for $11.14 mill | Jun 16, 2026 |
| GILD | CLUSTER | neutral | 2/10 | Two GILD executives (CFO and Chief Communications & Corporate Affairs Officer) sold a combined $559K in open-market shar | Jun 16, 2026 |
| HOWL | CLUSTER | bearish | 6/10 | Two insiders at Werewolf Therapeutics (HOWL) sold shares in a cluster, including Director Luke Evnin and 10% owner RA Ca | Jun 16, 2026 |
| ALVO | 424B5 | bearish | 7/10 | Alvotech is pricing a $85M underwritten public offering of 22.7M ordinary shares at $3.75/share (11.5% discount to last | Jun 16, 2026 |
| PHGE | 424B5 | bearish | 5/10 | BiomX filed a prospectus supplement to update its ATM offering capacity, authorizing up to $5,061,000 in common stock sa | Jun 16, 2026 |
| IMNN | 8-K | neutral | 2/10 | Imunon, Inc. filed an 8-K reporting the results of its 2026 Annual Meeting held on June 16, 2026. Stockholders approved | Jun 16, 2026 |
| IONS | CLUSTER | neutral | 2/10 | Two IONIS insiders (a Director and the EVP/Chief Development Officer) sold a combined $3.59M in open-market shares after | Jun 16, 2026 |
| VVOS | 8-K | bearish | 5/10 | Vivos Therapeutics announced its intention to file a registration statement for a proposed rights offering, where shareh | Jun 16, 2026 |
| CVM | 8-K | bearish | 6/10 | CEL-SCI Corporation completed a best-efforts offering of 2,500,000 shares at $1.00 per share for gross proceeds of $2.5M | Jun 16, 2026 |
| ELUT | 8-K | neutral | 3/10 | Elutia Inc. filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders, where shareholders approved a | Jun 16, 2026 |
| CDT | 8-K | bearish | 7/10 | CDT Equity Inc. entered into a $1.46M secured convertible loan with J.J. Astor & Co., issuing a $1.971M promissory note, | Jun 16, 2026 |
| PULM | 10-K/A | neutral | 2/10 | Pulmatrix filed an immaterial 10-K/A (Amendment No. 1) solely to correct a typographical error in the date of the Report | Jun 16, 2026 |
| TARS | 144 | neutral | 2/10 | Officer Jeffrey S. Farrow filed a Form 144 to sell 14,396 shares of Tarsus Pharmaceuticals common stock, valued at appro | Jun 16, 2026 |
| TVTX | 8-K | neutral | 2/10 | Travere Therapeutics disclosed the planned retirement of Chief Research Officer William Rote, effective February 17, 202 | Jun 16, 2026 |
| TVTX | CLUSTER | neutral | 2/10 | Two directors of Travere Therapeutics (TVTX) exercised stock options and immediately sold the resulting shares on June 1 | Jun 16, 2026 |
| ASRT | 8-K | bullish | 7/10 | Assertio Holdings completed its acquisition by Zydus Lifesciences on June 16, 2026. Shareholders received $23.50 per sha | Jun 16, 2026 |
| NBP | 6-K | neutral | 5/10 | NovaBridge Biosciences dismissed its auditor PwC and appointed Deloitte as its new independent registered public account | Jun 16, 2026 |
| SLXN | PRESS-RELEASE | neutral | 2/10 | Silexion Therapeutics, a clinical-stage biotech micro-cap ($2M market cap) developing RNAi therapies for KRAS-driven can | Jun 16, 2026 |
| ORGO | 8-K | neutral | 2/10 | Organogenesis Holdings Inc. filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders held on June 1 | Jun 16, 2026 |
| VRXA | 20-F | bearish | 6/10 | Veraxa Biotech AG completed a de-SPAC business combination on June 10, 2026, merging with Voyager Acquisition Corp. Conc | Jun 16, 2026 |
| CTTH | S-1/A | bearish | 5/10 | CTT Pharmaceutical Holdings filed Amendment No. 3 to its S-1 registration statement, registering 6,250,000 shares for re | Jun 16, 2026 |
| LKFT | 6-K | neutral | 2/10 | Lakefront Biotherapeutics disclosed the repurchase of 38,537 ordinary shares at a total cost of approximately €954,809 u | Jun 16, 2026 |